Advertisement

MMW - Fortschritte der Medizin

, Volume 161, Supplement 2, pp 28–32 | Cite as

Wirksamer Schutz

Präexpositionsprophylaxe — wie ist der aktuelle Stand?

  • Christoph D. SpinnerEmail author
FORTBILDUNG . ÜBERSICHT
  • 13 Downloads

Seit 2016 ist die Präexpositionsprophylaxe in Deutschland zugelassen. Hat sie gehalten, was man sich von ihr versprochen hat? Gibt es neue Medikamente? Was hat sich in der Betreuung gefährdeter Personen geändert?

HIV pre-exposure prophylaxis: how about current trends?

Keywords

HIV PrEP Germany 

Literatur

  1. 1.
    Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink H-J, Rockstroh JK et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151–8CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Huang X, Hou J, Song A, Liu X, Yang X, Xu J et al. Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. Front Pharmacol. Frontiers. 2018;9:1088–11CrossRefGoogle Scholar
  3. 3.
    Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151re125CrossRefGoogle Scholar
  4. 4.
    Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4CrossRefPubMedCentralGoogle Scholar
  5. 5.
    van de Vijver DAMC, Richter A-K, Boucher CAB, Gunsenheimer-Bartmeyer B, Kollan C, Nichols BE et al. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. Euro Surveill. 2019;24(7):1–9CrossRefGoogle Scholar
  6. 6.
    Nwokolo N, Hill A, McOwan A, Pozniak A. Rapidly declining HIV infection in MSM in central London. The Lancet HIV. 2017;4:e482–3CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS et al. Effects of Pre-exposure Prophylaxis for the Prevention of HIV Infection on Sexual Risk Behavior in Men Who Have Sex with Men: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;376:285Google Scholar
  8. 8.
    Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G et al. Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis. J Infect Dis. 2015;211:1211–8PubMedPubMedCentralGoogle Scholar
  9. 9.
    Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira JV, Hance RJ et al. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr. 2016;71:281–6CrossRefPubMedCentralGoogle Scholar
  10. 10.
    PhD PMH, PhD TL, PhD LM, MPH JK, PhD IZ, MPH TD et al. Articles Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17. The Lancet HIV. 2018;1–9.Google Scholar
  11. 11.
    Calabrese SK, Magnus M, Mayer KH, Krakower DS, Eldahan AI, Hawkins LAG et al. „Support Your Client at the Space That They’re in“: HIV Pre-Exposure Prophylaxis (PrEP) Prescribers’ Perspectives on PrEP-Related Risk Compensation. AIDS Patient Care STDS. 2017;31:196–204CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men. AIDS. 2016;30:2251–2.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. The Lancet HIV. 2017;4:e402–10CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Spinner CD, Boesecke C, Jordan C, Wyen C, Kümmerle T, Knecht G et al. Prevalence of asymptomatic sexually transmitted infections in HIV-positive men who have sex with men in Germany: results of a multicentre cross-sectional study. Infection. 2018;46:341–7CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Braun DL, Marzel A, Steffens D, Schreiber PW, Grube C, Scherrer AU et al. High rates of subsequent asymptomatic STIs and risky sexual behavior in patients initially presenting with primary HIV-1 infection. Clin Infect Dis. 2017;66:735–42CrossRefGoogle Scholar
  16. 16.
    Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW et al. Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study. Clin Infect Dis. 2017;65:712–8CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Deutsch-Österreichische Leitlinien zur HIV-Präexpositionsprophylaxe. Verfügbar unter: https://daignet.de/site-content/hiv-therapie/leitlinien-1/deutsch-oesterreichische-leitlinien-zur-hiv-praeexpositionsprophylaxe
  18. 18.
    Spinner CD, Hanhoff N, Krznaric I, Knecht G, Kuemmerle T, Ruesenberg R et al. 2016 PREP attitudes in Germany: high awareness and acceptance in MSM at risk of HIV. Infection. 2018;46:405–8CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der IsarMünchenDeutschland

Personalised recommendations